-
Gyre Therapeutics Inc NasdaqCM:GYRE Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Location: 12770 High Bluff Drive, San Diego, CA, 92130, United States | Website: https://www.gyretx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
841.3M
Cash
29.89M
Avg Qtr Burn
-1.664M
Short % of Float
12.72%
Insider Ownership
85.75%
Institutional Own.
2.81%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avatrombopag Details Thrombocytopenia , Chronic liver disease | Approved Quarterly sales | |
F351 (Hydronidone) Details Chronic hepatitis B, Liver fibrosis | Phase 3 Data readout | |
F573 Details Acute-on-Chronic liver failure | Phase 2 Data readout | |
F351 (Hydronidone) Details Metabolic dysfunction-associated steatohepatitis (“MASH”)-related fibrosis | Phase 2 Initiation | |
F351 (Hydronidone) Details Non-alcoholic steatohepatitis , Liver fibrosis | Phase 2a Initiation | |
F230 Details Pulmonary arterial hypertension | Phase 1 Initiation |